Kornimate/medical-research-clean huggingface dataset:
neural mechanisms of mindfulness-based cognitive therapy (mbct) for ptsd - covid related substudy

Conditions: Trauma

Summary: this clinical trial is a sub-study to treat participants that were not eligible in the main study (hum00152509/nct03874793) to receive mbct or mrt in hard hit covid-19 areas with trauma history and current covid-related distress. the purpose of this treatment-only sub-study is to see how eligible participants with life history of any trauma and are currently experiencing elevated covid-related stress are affected by two different ptsd therapies involving mind-body practices; mindfulness based cognitive therapy (mbct) and muscle relaxation therapy. the targeted individuals will reside in areas (washtenaw, wayne, and oakland counties in michigan, etc.) that have been affected by covid-19. participants will have assessments before and after 8 weeks of therapy (remote mbct or mrt).

this clinical trial is a sub-study to treat participants that were not eligible in the main study (hum00152509/nct03874793) to receive mbct or mrt in hard hit covid-19 areas with trauma history and current covid-related distress. the purpose of this treatment-only sub-study is to see how eligible participants with life history of any trauma and are currently experiencing elevated covid-related stress are affected by two different ptsd therapies involving mind-body practices; mindfulness based cognitive therapy (mbct) and muscle relaxation therapy. the targeted individuals will reside in areas (washtenaw, wayne, and oakland counties in michigan, etc.) that have been affected by covid-19. participants will have assessments before and after 8 weeks of therapy (remote mbct or mrt).

Eligibility criteria:
inclusion criteria: * covid distress sample: resides in geographical area heavily impacted by covid-19 have a history of trauma * has current elevated levels of covid related stress and/or distress (worry, repetitive negative thinking) (covid stress scale score \> 15, worry / repetitive negative thinking, penn state worry questionnaire (pswq) score \>35 ). exclusion criteria: * ptsd * suicide risk * psychosis * life history of schizophrenia * current substance dependence * other factors that preclude safe and meaningful participation in the study, at discretion of the pi and study team

Keywords: mindfulness-based cognitive therapy muscle relaxation group psychotherapy
predicting responses to exhausting, prolonged, and repeated exercise demands (prepared) for heat

Conditions: Hyperthermia; Fatigue; Heat

Summary: the overall goal of this project is to identify a work/rest cycle that allows for faster mission completion needed in emergency situations, compared to current army heat guidance, while mitigating heat strain and neuromuscular fatigue. this project will determine the trade-off between faster mission completion and risk of heat strain and physical performance decrements. completion of this project will allow military leaders to make informed decisions by understanding the impact of their choices on the magnitude of physical performance decrements and expected heat casualties, setting up hot weather missions for success.


Eligibility criteria:
inclusion criteria: * healthy individuals * physically active exclusion criteria: * history of cardiovascular, metabolic (such as clinical thyroid disease), respiratory, neural, or renal disease * hypertensive (systolic blood pressure \> 139 mmhg, diastolic blood pressure \> 89 mmhg) or tachycardic (heart rate \> 100 bpm) during the screening visit * taking medications or supplements known to effect physiologic responses to exercise or thermoregulation (e.g., beta blockers, omega-3 fatty acids, statins, aspirin) * tobacco or nicotine use currently or in the past six months * musculoskeletal injury expected to impact exercise in the protocol * a positive pregnancy test at any point in the study * study physician discretion based on any other medical condition or medication * inability to understand or follow instructions or the protocol * gastrointestinal disease or previous surgery prohibiting core temperature capsule use. participants with a contraindication can opt to insert the pill rectally as a suppository.
clinical & radiographic evaluation of neo mta versus white mta in revascularization of non-vital immature permanent teeth

Conditions: Nonvital Tooth

Summary: * to evaluate and compare the degree of tooth discoloration in tooth crowns induced by neo mta versus white mta over time. * evaluation of the effectiveness of neo mta as coronal plug in revascularization of immature teeth with necrotic pulp.

the new formulation of mta (neomta) does not contain bismuth oxide, will be used in revascularization of nonvital immature permanent anterior teeth. to evaluate the effectiveness of neo mta as coronal plug and compare the degree of tooth discoloration in tooth crowns induced by neo mta versus white mta over time.

Eligibility criteria:
inclusion criteria: * age of patients: 7-15years old. * free from any systemic diseases that may affect the normal healing process. * tooth with immature root apex. * traumatically or cariously exposed non vital permanent anterior tooth. * pulp space not needed for post and core for final restoration. * compliant patient/parent exclusion criteria: * patients having allergy to medicaments and antibiotics necessary to complete procedure. * tooth with vital pulp or complete root formation. * teeth with internal or external root resorption. * un-cooperative patients. * luxative injuries. * teeth with a root fracture * alveolar fracture * subjects with chronic systemic illness. * subjects with poor oral hygiene. * compromised remaining tooth structure as teeth with extensive loss of coronal tissue will require restoration with a post that will occupy the space required for blood clot formation.

Keywords: pulp revascularization endodontic regeneration neomta
genetics in parkinson's disease: behavioral and cognitive outcomes

Conditions: Parkinson Disease

Summary: the genetic landscape of parkinson's disease (pd) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving pd risk in a significant minority in pd cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic pd. this knowledge has the potential to have a major impact in the clinical care of people with pd. the goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in pd patients. patients will be assessed over time using test, questionnaire and standardised clinica scales. an initial assessment and annual follow-up assessments will be carried out for 5 years. researchers will compare data collected from patients with genetic mutation versus patients without mutation.


Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease (pd) * in use of dopaminergic medication (l-dopa and/or dopamine agonists) * genetic testing for mendelian forms of pd * able to provide informed consent to participate in the study exclusion criteria: * patients underwent deep brain stimulation (dbs) treatment
palliative care in improving quality of life in patients with newly diagnosed pancreatic cancer

Conditions: Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer

Summary: this pilot clinical trial studies a palliative care program in improving the quality of life of patients with newly diagnosed pancreatic cancer. palliative care is care given to patients who have a serious or life-threatening disease, and focuses on managing disease symptoms, side effects of treatment or the disease, and improving patient quality of life. studying a palliative care program used for other types of cancer may help doctors learn whether it can improve the quality of life of patients with pancreatic cancer.

primary objectives: i. to pilot-test an interdisciplinary palliative care planning intervention (pcpi) in pancreatic cancer. specifically, to describe patients' satisfaction with the timing, content, and delivery of the pcpi intervention. secondary objectives: i. to pilot-test all selected measures for the study, including measures for healthcare resource utilization, overall cost, and patient/family out of pocket expenses. ii. the long-term objective of this pilot study is to conduct a larger pcpi intervention study for pancreatic cancer patients and evaluate its impact on quality of life (qol), symptom intensity, healthcare resource utilization, and healthcare costs. outline: patients receive a handbook titled "supporting you during cancer treatment" with educational material on qol issues. patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. at the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs. after completion of study, patients are followed up at 1 and 2 months.

Eligibility criteria:
inclusion criteria: * pathologically confirmed, new diagnosis of borderline resectable, locally advanced resectable/unresectable, or metastatic pancreatic cancer * patients who are scheduled to receive treatments (neoadjuvant therapy, surgery, adjuvant therapy, or palliative chemotherapy) at city of hope (coh) * all subjects must have the ability to understand and the willingness to provide informed consent exclusion criteria: * subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
detection of upper gastrointestinal (gi) bleeding using a novel bleeding sensor capsule -a pilot study

Conditions: Upper Gastrointestinal Bleeding

Summary: this is a multi-center, prospective, non-randomized, open-label, exploratory clinical investigation performed to evaluate safety and effectiveness of the pillsense system when used for detection of blood in the stomach of patients suspected to have an upper gastrointestinal bleed (ugib).

the pillsense system consists of the pillsense capsule, an atraumatic, ingestible, and disposable capsule and pillsense receiver, an external real-time monitor for results display. the pillsense capsule is a non-invasive, single use device designed to detect blood in the stomach and wirelessly transmit the data to the external pillsense receiver. the receiver is a handheld device which displays real-time information gathered from the capsule and clearly displays results, "blood detected" or "no blood detected". all enrolled participants were admitted for suspected ugib and were required to ingest a pillsense capsule followed by esophagogastroduodenoscopy (egd) within 1 hour of pillsense capsule administration. all patients underwent standard endoscopy following pillsense capsule evaluation and results were compared with the pillsense system result, i.e., "blood detected" or "no blood detected". the study was also designed to confirm transit of the pillsense capsule through the gi tract and patient tolerability of the pillsense capsule.

Eligibility criteria:
inclusion criteria: * age 18 -80 years * ability to give written informed consent * clinical suspicion of bleeding exclusion criteria: 1. circulatory or hemodynamic instability with a clear need for urgent endoscopy or surgery (systolic blood pressure \ 100 / min) 2. known current stenosis of the gi tract 3. subject is using a pacemaker or other implantable electrical device 4. dysphagia or difficulties in swallowing pills the size of the capsule 5. history of achalasia or known esophageal dysmotility 6. history of gastroparesis 7. history of severe constipation (1 bowel movement per week or less) 8. patients who are currently pregnant or breastfeeding, or intend to become pregnant during the investigation 9. presence of psychological issues preventing participation 10. stomach bezoar 11. history of crohn disease 12. history of diverticulitis 13. history of bowel obstruction 14. suspected gastrointestinal tumor disease 15. planned mri investigation (mri needed before the capsule is excreted)
effectiveness study of cbt for anxiety in children

Conditions: Separation Anxiety Disorder; Social Anxiety Disorder; Generalized Anxiety Disorder

Summary: the study aims to evaluate the effectiveness of a cognitive behaviour therapy program (friends) for anxiety disorders in children aged 8-15 years who have been referred to child and adolescent mental health clinics in western norway.

cognitive behaviour therapy (cbt) has been shown to be an efficacious treatment for anxiety disorders in youths when delivered in university settings. however, there is a lack of studies evaluating the effectiveness of cbt in regular clinical settings. the current study will compare a cbt program developed for anxiety in youths (the friends program by paula barrett, australia), with a wait-list control condition. group and individual treatment will also be compared in the study. groups will be divided by age, with younger including 8-12-year-olds, and older 12-15-year-olds. parents are also involved at the end of all therapy sessions, as well as in separate parent sessions. assessment and treatment is delivered by clinicians working in seven outpatient clinics in western norway. there will be 10 therapy sessions, with booster sessions 4 and 12 weeks later. effectiveness will be evaluated post-treatment, and at 1 and 5 years follow-up. the study will have a randomized design. children randomized to the wait-list condition will be offered treatment if they still meet inclusion criteria after the waiting period.

Eligibility criteria:
inclusion criteria: * meeting dsm-iv criteria for separation anxiety, social anxiety or generalized anxiety disorder based on the adis interview schedule exclusion criteria: * pervasive developmental disorders, selective mutism, mental retardation * having severe obsessional/compulsive, conduct or language problems.
acute effects of dynamic stretching, plyometrics, and loading on achilles tendon properties and performance outcomes

Conditions: Tendon Injuries

Summary: the study will be looking at acute changes in achilles tendon properties and changes in a vertical single leg hop following an exercise intervention. the three exercise interventions will be randomized and take place on separate days 1 week apart. the three exercise interventions are aarom, slow load, and plyometrics.

the purpose of the study is to determine if there are acute changes in achilles tendon properties and changes in performance based on what tendon exercise intervention is being used. about 70 people will take part in this research.

Eligibility criteria:
inclusion criteria: * college student exclusion criteria: * unable to complete interventions
dexmedetomidine as an adjuvant to bupivacaine in ultrasound-guided quadratus lumborum block for postoperative analgesia in laparoscopic cholecystectomy

Conditions: Dexmedetomidine; Bupivacaine; Ultrasound-Guided; Quadratus Lumborum Block; Postoperative Analgesia; Laparoscopic Cholecystectomy

Summary: the aim of this study is to evaluate the effect of adding dexmedctomidinc as adjuvant to bubivacaine in ultrasound-guided quadratus lumborum block for postoperative analgesia in laparoscopic cholecystectomy.

when compared to conventional surgery, laparoscopic cholecystectomy is less invasive and leads to less postoperative pain. however, the postoperative pain following laparoscopic cholecystectomy consists of both somatic and visceral components with pain originating from port entry' wounds, gallbladder resection and abdominal insufflation that leads to peritoneal distention and peritoneal damage. quadratus lamborum block (qlb) is abdominal truncal block that provides both somatic and visceral analgesia for both upper and lower abdominal surgical procedures, it was first introduced by blanco.currently there are 4 approaches described for qlb: lateral, posterior, anterior and intramuscular. transmuscular (anterior) qlb type 3 block involves injection in the plane between the psoas major (pm) and the ql muscles studies have reported spread of the injectate to the thoracic paravertebral space, as well as the spinal nerve which runs anterior to the ql muscle

Eligibility criteria:
inclusion criteria: * aged 21-65 years. * both genders. * american society of anesthesiology (asa) class l, ii undergoing elective laparoscopic cholecystectomy exclusion criteria: * patient refusal * history of allergy to local anesthetic. * liver or renal pathology affecting drug elimination * menta!dysfunction or cognitive disorders. * patients on chronic pain medications. * body mass index \> 40 kg/m2. * coagulopathy
stone clearance in patients with upper ureteric stones using extracorporeal shock wave lithotripsy compared with extracorporeal shock wave lithotripsy combined with tamsulosin therapy

Conditions: Renal Stone

Summary: extracorporeal shock wave lithotripsy (eswl) is the least invasive and effective treatment for upper ureteric stones with a stone clearance rate of 60-90%. tamsulosin is an alpha-blocker widely used in urological practice to relax smooth muscle of the prostate and bladder neck. its role as part of medical expulsion therapy for the treatment of patients with kidney and ureteric stones has proved to be of considerable success. however, its role in clearing upper ureteric stones as an adjunct to eswl is controversial. therefore, this study will be conducted to evaluate its role in stone clearance along with extracorporeal shock wave lithotripsy in patients with upper ureteric stones


Eligibility criteria:
inclusion criteria: * single upper ureteric stone * size ranging from 6-15 mm * stones history less than 6 months exclusion criteria: * patients with urinary tract infection * multiple ureteric stones, * presence of a ureteric stricture distal to the stone, * previous unsuccessful eswl, * concomitant use of calcium channel blockers or alpha-adrenergic antagonists * patients with abnormal coagulation profile
a study to evaluate the impact on skin (injection site) reactions of using alcohol wipes prior to daily injections of copaxone®.

Conditions: Multiple Sclerosis

Summary: this study is designed to compare injection site reactions with or without the use of alcohol wipes prior to performing the patients' daily copaxone® injection.


Eligibility criteria:
inclusion criteria: * male or female * 18 years of age or older * diagnosis of rrms * beginning or recently (within 3 months) began self-injecting copaxone® subcutaneously exclusion criteria: * unable to perform subcutaneous self-injection * pregnant, or trying to become pregnant, or breast feeding during the study

Keywords: copaxone
comparison of retinal damage in icl implantation using 3d visualization system vs. microscope

Conditions: High Myopia

Summary: implantable collamer lens (icl) implantation is considered one of the most effective surgical treatments for high myopia. the procedure primarily involves adjusting the position of the icl within the eye. however, precise calculation of the icl optical power may cause the surgical light source to remain focused on the macular area during this process, potentially leading to iatrogenic light-induced damage. theoretically, the combination of a 3d visualization surgical system and coaxial illumination technology can reduce the illumination intensity and decrease iatrogenic light damage. this study aims to compare the retinal physiological changes in patients undergoing icl surgery through 3d visualization surgical system with coaxial illumination versus a traditional microscope with standard illumination.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of high myopic * aged 18-40 years * desire to improve their refractive status via icl surgery * relatively stable refractive error (change ≤ 0.50 d per year for two consecutive years) * central anterior chamber depth ≥ 2.8 mm * open angles * corneal endothelial cell density ≥ 2000 cells/mm2. exclusion criteria: * cataracts * corneal diseases, * glaucoma, * nystagmus, * strabismus, * lens subluxation, * severe vitreoretinal diseases, * other ocular diseases * a history of ocular trauma * a history of ocular surgery
a trial to compare blood concentration levels of semaglutide following subcutaneous injections of semaglutide 1 mg by 2 different devices (the dv3372 device and by the pds290 semaglutide pen-injector)

Conditions: Diabetes Mellitus, Type 2

Summary: this study compares semaglutide in two different injection tools called "pds290" and "dv3372". the study aims to show similar levels of semaglutide in the blood when using either of the two injection tools. the researchers also want to look at how well the injection tools work. participants will either receive semaglutide using the pds290 or the dv3372 injection tool. this is decided by chance, like flipping a coin. this is called randomisation. semaglutide is an approved medicine (thus available on the market) for people with type 2 diabetes. semaglutide will be injected subcutaneously (injection under the skin). participants will get a total of 5 injections with semaglutide. the study will last for a maximum of 86 days. participants will have 17 scheduled site visits with the study physician or study staff at the study centre. for one of the visits participants will stay at the research unit for 4 days and 3 nights. participants cannot take part in this study if participants have any disorder that the doctor thinks is a health problem. only healthy men and women are allowed to take part. women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.


Eligibility criteria:
inclusion criteria: - male or female, aged 18 to 55 years (both inclusive) at the time of signing informed consent. - body mass index between 20.0 and 29.9 kg/m\^2 (both inclusive) and weight between 55.0 and 90.0 kg (both inclusive). - considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: - female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods. - any disorder which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol. - use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, highly effective contraceptives and occasional use of paracetamol (not allowed within 24 hours before screening), within 14 days prior to the day of screening. - abuse or intake of alcohol, defined as any of the below: 1) known or suspected alcohol abuse within 1 year prior to the day of screening (defined as regular intake of more than an average intake of 24 g alcohol daily for men and 12 g alcohol daily for women -12 g of alcohol equals about 300 ml of beer or lager, 100 ml of wine, or 25 ml spirits) or 2) positive alcohol test at screening. - abuse or intake of drugs, defined as any of the below: 1) known or suspected drug/chemical substance abuse within 1 year prior to the day of screening or 2) positive drug of abuse test at screening.